Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging TAAP™ and MPAR™, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Company profile
Ticker
ENSC, ENSCW
Exchange
Website
CEO
Daniel B. Silvers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Leisure Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Covistat, Inc. • EBI OpCo, Inc. • EBI Operating, Inc. ...
ENSC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-A12G/A
Registration of securities (amended)
8 Feb 23
8-K
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
7 Feb 23
424B5
Prospectus supplement for primary offering
6 Feb 23
8-K
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock
1 Feb 23
8-A12G
Registration of securities
1 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jan 23
S-3
Shelf registration
30 Jan 23
8-K
Other Events
18 Jan 23
EFFECT
Notice of effectiveness
18 Jan 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
Latest ownership filings
SC 13G
Lincoln Park Capital Fund, LLC
7 Feb 23
4
BOB G GOWER
1 Feb 23
SC 13G
CVI Investments, Inc.
16 Dec 22
SC 13D/A
Silvers Daniel B.
7 Jul 22
4
William H Chang
27 Jun 22
4
Steven Robert Martin
27 Jun 22
4
Lee M. Rauch
27 Jun 22
4
BOB G GOWER
27 Jun 22
4
Curtis Rosebraugh
27 Jun 22
4
Andrew Benton
27 Jun 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.50 mm | 4.50 mm | 4.50 mm | 4.50 mm | 4.50 mm | 4.50 mm |
| Cash burn (monthly) | (no burn) | 195.22 k | 2.05 mm | 1.67 mm | 2.24 mm | 1.53 mm |
| Cash used (since last report) | n/a | 849.04 k | 8.94 mm | 7.26 mm | 9.73 mm | 6.65 mm |
| Cash remaining | n/a | 3.65 mm | -4.43 mm | -2.76 mm | -5.23 mm | -2.15 mm |
| Runway (months of cash) | n/a | 18.7 | -2.2 | -1.7 | -2.3 | -1.4 |
Institutional ownership, Q3 2022
73.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 19 |
| Opened positions | 4 |
| Closed positions | 8 |
| Increased positions | 6 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 30.39 mm |
| Total shares | 8.47 mm |
| Total puts | 0.00 |
| Total calls | 10.70 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Silvers Daniel B. | 2.88 mm | $2.50 mm |
| HG Vora Capital Management | 2.46 mm | $529.00 k |
| Hydra LAC | 1.87 mm | $27.07 mm |
| Vanguard | 315.83 k | $68.00 k |
| BLK Blackrock | 234.24 k | $50.00 k |
| SF Stifel Financial | 216.64 k | $47.00 k |
| Cerity Partners | 150.00 k | $32.00 k |
| Geode Capital Management | 130.52 k | $28.00 k |
| UBS UBS Group AG - Registered Shares | 52.14 k | $11.00 k |
| NTRS Northern Trust | 51.09 k | $11.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Dec 22 | Bob G Gower | Buy | Acquire P | No | No | 1.4 | 357,143 | 500.00 k | 753,095 | |
| 9 Dec 22 | Bob G Gower | Common Stock | Grant | Acquire A | No | No | 1.4 | 714,286 | 1.00 mm | 716,365 |
| 23 Jun 22 | Adam Levin | Stock Option Common Stock | Grant | Acquire A | No | No | 0.425 | 15,000 | 6.38 k | 35,000 |
| 23 Jun 22 | Curtis Rosebraugh | Stock Option Common Stock | Grant | Acquire A | No | No | 0.425 | 20,000 | 8.50 k | 35,000 |
| 23 Jun 22 | Andrew Benton | Stock Option Common Stock | Grant | Acquire A | No | No | 0.425 | 15,000 | 6.38 k | 100,850 |
| 23 Jun 22 | Bob G Gower | Stock Option Common Stock | Grant | Acquire A | No | No | 0.425 | 15,000 | 6.38 k | 41,585 |
News
Over $12 Million Bet On TD Holdings? Check Out These 3 Penny Stocks Insiders Are Buying
2 Feb 23
Why Ensysce Biosciences Stock Is Exploding Higher During Wednesday's Session
25 Jan 23
Nasdaq Falls 50 Points; eHealth Shares Spike Higher
25 Jan 23
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
25 Jan 23
Nasdaq Down Over 200 Points; AT&T Posts Upbeat Earnings
25 Jan 23
Press releases
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
7 Feb 23
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
3 Feb 23
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
1 Feb 23
Thinking about buying stock in Esports Entertainment, Faraday Future Intelligent Electric, Ensysce Biosciences, NVIDIA, or Mullen Automotive?
25 Jan 23
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
25 Jan 23